Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, is revolutionizing life science research with the launch of its multimodal therapy AI guidance platform. This innovative software, designed to optimize curative lung cancer treatment, will be unveiled at the 2024 ASCO Annual Meeting in Chicago.
Lung cancer often goes undetected until it reaches an advanced stage, leading to limited treatment options and poor outcomes. However, Optellum’s Virtual Nodule Clinic offers a solution by providing FDA-cleared decision support for early-stage lung cancer. By combining Patient Discovery AI with clinically validated Lung Cancer Prediction (LCP) score, clinicians can identify at-risk patients and prioritize them for interventions.
Early diagnosis is crucial for offering patients curative treatment options, as recurrence rates for Stage I-II NSCLC patients can be significant. Optellum’s AI solutions aim to assist thoracic oncology teams in optimizing treatment strategies by providing accurate prognosis of recurrence risk. This information can help tailor surgical resection and ensure appropriate treatments are offered to those at risk.
At the ASCO 2024 Annual Meeting, Optellum will showcase their precision lung cancer care AI solutions. Their clinical partners will present results of AI-guided recurrence prognosis, demonstrating increased sensitivity for recurrence compared to traditional staging methods. Attendees can also see Optellum’s AI solutions in action at the CancerLinQ and ConcertAI booths.
Christine D. Berg, M.D., a leading expert in lung cancer screening, praises Optellum’s innovative approach to prognosis determination, stating that radiomic tools combined with demographics can enhance decision-making early in the patient’s journey and improve outcomes. Optellum’s Founder & Chief Business Officer, Václav Potěšil, envisions their multi-modal AI platform as the “operating system” for precision lung cancer care, guiding patients from early identification to treatment response prediction.
Optellum’s mission is to provide AI decision-support software that aids physicians in early diagnosis and optimal treatment for lung disease patients. The company has achieved FDA clearance and reimbursement for its software application in lung cancer diagnosis and has formed strategic partnerships with key industry players. With headquarters in Oxford, UK, and a US office at the Texas Medical Center, Optellum is dedicated to democratizing access to life-saving early diagnosis and precision treatment for all patients who can benefit. To learn more about Optellum, visit their website or follow them on LinkedIn.
Source link
